1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

29 Sep 2023
Admin
News Article

BioCity Biopharm and AstraZeneca Enter into Collaboration Agreement

BioCity Biopharma and AstraZeneca have entered into a collaborative agreement aimed at conducting a Phase Ib/II clinical study.

The collaboration between BioCity and AstraZeneca aims to assess the potential of combining BC3402 with durvalumab (IMFINZI) to enhance the clinical outcomes for individuals diagnosed with hepatocellular carcinoma (HCC).

The purpose of this study is to assess the safety and effectiveness of BioCity's BC3402, a monoclonal antibody designed to target TIM-3 (T cell immunoglobulin and mucin domain-containing protein 3), in combination with AstraZeneca's anti-PD-L1 monoclonal antibody IMFINZI, also known as durvalumab.

The focus of this joint research effort is to explore the potential treatment benefits of this combination therapy for patients with advanced hepatocellular carcinoma (HCC) in China.

BC3402 is a highly anti-TIM-3 monoclonal antibody (mAb) that outshines its counterparts in terms of binding affinity, making it a potential best-in-class candidate. This antibody possesses the unique capability to bind to multiple epitopes on TIM-3, a critical immune checkpoint protein. Moreover, BC3402 has demonstrated its effectiveness in blocking the interactions of TIM-3 with important molecules such as CEACAM1, PtdSer, and Gal-9.

Furthermore, BC3402 has showcased remarkable synergistic effects when combined with monoclonal antibodies targeting PD-1 and CTLA-4. These are pivotal targets in the clinical treatment of liver cancer. BC3402 has the potential to enhance the efficacy of immune checkpoint inhibitors, holding promise for more effective liver cancer therapies.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!